We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Smarter Blood Tests Deliver Faster Diagnoses and Improved Outcomes

By LabMedica International staff writers
Posted on 19 Nov 2024

It has long been established that the earlier a disease is detected, the better the chances for a positive patient outcome. More...

A novel method now offers an in-depth analysis of proteins in plasma, uncovering biomarkers that can help researchers and eventually clinicians identify diseases at an earlier stage.

This pioneering methodology for deep analysis of proteins in plasma was developed by a multidisciplinary team of researchers from Michigan State University (East Lansing, MI, USA), in collaboration with other experts. The new approach minimizes the interference from common blood proteins, making it possible to detect lesser-known, low-abundance proteins that are often key in diagnosing diseases. By introducing small molecules into the blood sample, these important proteins are exposed on the surface of nanoparticles, enhancing their visibility for analysis through mass spectrometry—a technique that separates and examines ionized particles using electric and magnetic fields.

This breakthrough testing method, published in Nature Communications, contributes to the advancement of precision medicine. Unlike the traditional "one-size-fits-all" treatment approach, precision medicine customizes healthcare for an individual's genetics, environment, and lifestyle, offering more targeted and effective solutions. This approach has shown particular promise in fields like cancer research, where tumor genetic profiling can result in improved outcomes and reduced side effects.

“Our innovative approach significantly reduces the masking effects of highly abundant plasma proteins, which often hinder the detection of critical biomarkers in human plasma,” said Morteza Mahmoudi, associate professor in the Department of Radiology and Precision Health Program in the MSU College of Human Medicine. “By minimizing these interactions, we can increase the visibility and identification of low-abundance proteins, making it easier to detect important biomarkers that would otherwise remain hidden. This enhancement leads to improved diagnostic capabilities, allowing for more precise and earlier detection of diseases.”


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Powered by OptraSCAN’s patented OS‑SiA technology, the platform performs scanning, indexing, and AI‑driven analysis simultaneously (Photo courtesy of OptraSCAN)

New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow

Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.